Patients with metastatic ovarian cancer exhibit significantly lower 5-year survival rates compared to those with primary ovarian cancer, and oophorectomy demonstrates limited impact on prognosis.[14] Furthermore, ALK-positive NSCLC is characterized by highly aggressive biological behavior, contributing to poor clinical outcomes. This evidence concerns the gene ALK and ovarian carcinoma.